

## OSE Immunotherapeutics Launches Newsletter for Individual Shareholders

**NANTES, France, July 17, 2025, 6:30pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)**, a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs, today launched the inaugural edition of its Newsletter, designed specifically for individual shareholders and investors in France and internationally.

*" This year, OSE Immunotherapeutics celebrates the 10<sup>th</sup> anniversary of its listing on Euronext Paris and we are delighted to introduce this new communication channel for our valued individual shareholders" said Fiona Olivier, Chief Corporate Affairs & Investor Relations Officer of OSE Immunotherapeutics. " Beyond providing updates on Company developments, the Newsletter gives us an opportunity to shine a spotlight on our teams and offer deeper insights into topics that are typically only touched on in press releases. It's also a way for us to express our appreciation for the continued trust and support of our investor community. "*

Published regularly in French and English, the Newsletter will be available in the "Investors" section of the OSE Immunotherapeutics website. To subscribe to receive our Newsletters: <https://www.ose-immuno.com/en/newsletters-2/>

### ABOUT OSE IMMUNOTHERAPEUTICS

OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: [www.ose-immuno.com](http://www.ose-immuno.com). Click and follow us on LinkedIn.

Click and follow us on LinkedIn.



### Contacts

**Fiona Olivier**

[fiona.olivier@ose-immuno.com](mailto:fiona.olivier@ose-immuno.com)

**Sylvie Détry**

[sylvie.detry@ose-immuno.com](mailto:sylvie.detry@ose-immuno.com)

**France Contact Media:**

**FP2COM**

Florence Portejoie

[fportejoie@fp2com.fr](mailto:fportejoie@fp2com.fr)

+33 6 07 768 283

**U.S. Contact Media:**

RooneyPartners LLC

Kate Barrette

[kbarrette@rooneypartners.com](mailto:kbarrette@rooneypartners.com)

+1 212 223 0561

### Forward-looking statements

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.



These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.